Publications & News | SILLAJEN

Publications & News

Targeting, Attacking, and Eradicating Cancers®

Publications & News

게시판

Total 31. ˙ 3/4 Page

11 SillaJen to use IPO proceeds to fund clinical trial of liver cancer drug in 11 countries 2016-11-14
10 SillaJen Announces Commercial Manufacturing Agreement with ABL Europe For Lead Oncolytic Virus, Pexa-Vec 2016-05-17
9 SillaJen Enrolls First U.S. Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer 2016-03-29
8 SillaJen Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer 2016-01-06
7 SillaJen Presents Data Demonstrating Pexa-Vec Synergy with Angiogenesis Inhibitors: A Collaboration with University of California, San Francisco 2015-06-29
6 SillaJen Announces Agreement with the FDA for a Special Protocol Assessment for Upcoming Phase 3 Pexa-Vec Trial in Advanced Liver Cancer 2015-04-20
5 Nature: Drug Development: Try and try again 2014-12-04
4 SillaJen Biotherapeutics To Present at the BIO Business Forum 2014-07-20
3 SillaJen Biotherapeutics Announces Completion of Name Change Following Acquisition of Jennerex 2014-07-19
2 SillaJen Announces Completion of Jennerex, Inc. Acquisition 2014-03-17